Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

Gilead’s deal­mak­ing spree, part of bio­phar­ma’s “blis­ter­ing” M&A this year, con­tin­ued on Tues­day with a con­sum­ma­tion of on­col­o­gy and in­flam­ma­tion start­up XinThera.

Af­ter deals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER